Charles River Laboratories
251 Ballardvale Street
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
418 articles with Charles River Laboratories
Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call
Charles River Laboratories International, Inc. will release fourth-quarter and full-year 2019 financial results and provide 2020 guidance on Tuesday, February 11th, before the market opens.
Charles River will use its strengths to help develop potential drug candidates across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience and rare disease.
Charles River Laboratories International, Inc. announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14th, at 9:30 a.m. PST, followed by a question and answer session at 10:00 a.m. PST.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million in cash, or $25.40 per HemaCare share. HemaCare will become part of Charles River’s Research Models and Services segment.
12/16/2019Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.
Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies
Partnership will leverage Bit Bio’s unique ability to generate authentic human cells at scale
Expanded antibody library expedites the drug discovery process
Update adds over 100 new tumor models and 150 new bioinformatic data sets, increasing translational power of the Compendium
Management will present an overview of Charles River’s strategic focus and business developments.
Charles River Laboratories International, Inc. reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3 million in the third quarter of 2018..
Charles River Laboratories International, Inc. announced that it has closed its previously announced offering of $500 million in aggregate principal amount of its 4.25% senior notes due 2028 in an unregistered offering.
A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:00 a.m. ET.
The meeting, which brings together more than 30,000 researchers from 70 countries, will take place from October 19-23, in Chicago, Illinois.
The Consortium is a global charity-industry partnership aimed at funding promising research from academia and helping progress projects with the scale and strength of industry supporters.
Charles River Laboratories International, Inc. announced the appointment of Virginia M. Wilson, the recently retired Senior Executive Vice President and Chief Financial Officer of Teachers Insurance and Annuity Association of America, to its Board of Directors.
New EndoScan-V™ endotoxin detection software and Celsis® automated detection platform for rapid sterility introduced to address unmet industry needs
The two-day event will highlight strategies for delivering drugs to patients faster
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
Charles River Laboratories International, Inc. reported its results for the second quarter of 2019.
Charles River Laboratories International, Inc. will release second-quarter 2019 financial results on Wednesday, July 31st, before the market opens.